RETRACTED: Resveratrol Inhibits the Migration and Metastasis of MDA-MB-231 Human Breast Cancer by Reversing TGF-β1-Induced Epithelial-Mesenchymal Transition
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Metastasis is a major cause of death in patients with breast cancer. In the process of cancer development, epithelial-mesenchymal transition (EMT) is crucial to promoting the invasion and migration of tumor cells. In a previous study, the role of resveratrol in migration and metastasis was investigated in MDA-MB-231 (MDA231) human breast cancer cells and a xenograft-bearing mouse model. Additionally, the related mechanism was explored. In the present study, in vitro Transwell assays showed that resveratrol can inhibit the migration of transforming growth factor (TGF)-β1-induced MDA231 cells in a concentration-dependent manner. An enzyme-linked immunosorbent assay (ELISA) showed that resveratrol can reduce the secretion of matrix metalloproteinase (MMP)-2 and MMP-9. Immunofluorescence was performed to confirm the expression of EMT-related markers. Immunofluorescence assays confirmed that resveratrol changed the expression of the EMT-related markers E-cadherin and vimentin. Western blot analysis demonstrated that resveratrol decreased the expression levels of MMP-2, MMP-9, Fibronectin, α-SMA, P-PI3K, P-AKT, Smad2, Smad3, P-Smad2, P-Smad3, vimentin, Snail1, and Slug, as well as increased the expression levels of E-cadherin in MDA231 cells. In vivo, resveratrol inhibited lung metastasis in a mouse model bearing MDA231 human breast cancer xenografts without marked changes in body weight or liver and kidney function. These results indicate that resveratrol inhibits the migration of MDA231 cells by reversing TGF-β1-induced EMT and inhibits the lung metastasis of MDA231 human breast cancer in a xenograft-bearing mouse model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4697-y · Cited by 439 · cited 1×
“Moreover, previous research has found that a PI3K/AKT inhibitor reversed EMT [39].”
A comprehensive review of the health perspectives of resveratrol
Rauf, A., Imran, M., Suleria, H. A. R., Ahmad, B., Peters, D. G., & Mubarak, M. S. (2017) · Food & Function · doi:10.1039/c7fo01300k · Cited by 286 · cited 1×
“This compound has many types of biological activities and pharmacological effects [13].”
BackgroundYang, H., Zheng, Y., Li, T. W. H., Peng, H., Fernandez-Ramos, D., Martínez-Chantar, M. L., Rojas, A. L., Mato, J. M., & Lu, S. C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.487157 · Cited by 44 · cited 1×
“Studies have shown that resveratrol can inhibit the initiation and progression of various tumors, such as liver cancer and breast cancer [14,15].”
Background
Cited by
Potential Adverse Effects of Resveratrol: A Literature Review
Shaito, A., Posadino, A. M., Younes, N., Hasan, H., Halabi, S., Alhababi, D., Al-Mohannadi, A., Abdel-Rahman, W. M., Eid, A. H., Nasrallah, G. K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062084 · Cited by 716
Metadata
- Authors
- Sun, Y., Zhou, Q.-M., Lu, Y.-Y., Zhang, H., Chen, Q.-L., Zhao, M., & Su, S.-B.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2019-03-21
- Volume
- 24
- Issue
- 6
- Pages
- 1131
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2923194742
- Cited by
- 164
- References
- 4
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.